Alazami syndrome is a rare genetic condition that affects growth, learning, and facial development. Features often include short stature, delayed speech, intellectual disability, and distinctive facial traits. Alazami syndrome is lifelong, and signs are usually noticed in infancy or early childhood. Many people with Alazami syndrome live into adulthood, but health needs vary by individual. Care focuses on supportive therapies, such as early intervention, speech and physical therapy, educational support, and regular checkups to monitor development and growth.
Overview
Alazami syndromeSymptoms
Alazami syndrome features slow growth with short stature, small head size, and developmental delay, especially speech. Many have learning disability, facial traits, and sometimes skeletal differences or seizures. Early signs of Alazami syndrome are noticed in infancy or early childhood.
Outlook and prognosis
Many living with Alazami syndrome have lifelong learning differences and short stature, with medical needs that vary from mild to complex. Early therapies and coordinated care can support communication, mobility, and overall health. Life expectancy depends on associated features, especially heart or airway issues.
Causes and risk factors
Alazami syndrome results from inheriting two altered copies of the LARP7 gene (autosomal recessive), usually from carrier parents. Risk of Alazami syndrome increases with parental consanguinity; severity may vary, but environment and lifestyle have minimal influence on expression.
Genetic influences
Genetics are central in Alazami syndrome. It results from inherited changes in the LARP7 gene, usually in an autosomal recessive pattern. Genetic testing confirms the diagnosis, guides family planning, and supports carrier testing for relatives.
Diagnosis
Doctors usually suspect Alazami syndrome from clinical features seen at infancy or early childhood. The genetic diagnosis of Alazami syndrome is confirmed by LARP7 testing, often via exome panels. Imaging and specialist assessments help document features and guide care.
Treatment and drugs
Treatment for Alazami syndrome centers on supportive, coordinated care. Plans often include early developmental therapies, seizure management if needed, hearing and vision support, growth and nutrition guidance, and monitoring of heart, kidneys, and hormones. Genetic counseling helps families plan and connect to resources.
Symptoms
Early features of Alazami syndrome can include feeding difficulties, slower growth, and delayed milestones in movement and speech. Features vary from person to person and can change over time. Many families notice a baby who tires during feeds or a toddler who needs extra support with language, balance, or coordination.
Babies may gain length and weight more slowly than peers, and children with Alazami syndrome often have short stature. Doctors track growth over time to see the pattern. This can affect clothing sizes and how well car seats or strollers fit.
Head size is often smaller than average (microcephaly). Hats and helmets may fit differently, and doctors measure head circumference at each visit.
Sitting, crawling, or walking may happen later than typical in Alazami syndrome. Extra time and therapy can help build these skills.
First words and sentences may come later. Many benefit from speech therapy to support understanding and expression.
How people usually first notice Alazami syndrome?
Families often notice something is different in the first year of life: babies may have slow growth (shorter length/height), feeding difficulties, and later-than-expected milestones like rolling, sitting, or babbling. Doctors may point out distinctive facial features on exam—such as deeply set eyes, a small chin, and a broad nasal bridge—and may also find small head size (microcephaly) and low muscle tone, which together raise concern for a genetic condition. For many, the first signs of Alazami syndrome emerge during infancy or early childhood through this combination of developmental delays, characteristic features, and growth patterns, prompting referral for genetic testing.
Types of Alazami syndrome
Alazami syndrome is a rare genetic condition linked to changes in the LARP7 gene, and there are no widely accepted clinical subtypes. People with Alazami syndrome can look quite different from one another, with variation in growth, learning, and facial features. Symptoms don’t always look the same for everyone. Because no distinct variants of Alazami syndrome are recognized, discussions about types of Alazami syndrome usually refer to individual differences rather than formal categories.
No recognized variants
There are currently no widely accepted clinical variants or subtypes of Alazami syndrome. Differences in severity are thought to relate to the specific LARP7 change and individual factors rather than separate types.
What genetics can tell you about symptoms
Changes in the LARP7 gene reduce a protein that helps control growth signals, which often leads to short stature, delayed speech, intellectual disability, distinctive facial features, and sometimes heart or skeletal differences. The same genetic change can look different between people, even within families.
Causes and risk factors
Alazami syndrome is caused by changes in a gene called LARP7 that are inherited from both parents. The chance is higher when both parents are carriers, in families with known cases, or when parents are related. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Environment and lifestyle do not cause Alazami syndrome, but good prenatal care, nutrition, and early therapies can lower complications. Ask your doctor about carrier screening and genetic testing, especially if early symptoms of Alazami syndrome were seen in an older child.
Environmental and biological risk factors
When you’re trying to understand what might raise the chance of Alazami syndrome, it’s natural to look at age, infections, medicines, or other exposures during pregnancy. So far, evidence points away from most of these factors and toward influences present from the very start of development. Doctors often group risks into internal (biological) and external (environmental). Here’s what research and clinical experience say about environmental risk factors for Alazami syndrome and body-related factors that have—or have not—shown a connection.
No clear link between older parental age and Alazami syndrome. Unlike some conditions tied to age-related changes in eggs or sperm, this syndrome has not shown a consistent age effect.
Conditions such as pre-existing diabetes or thyroid disease are not known to increase the chance of this syndrome. They may influence pregnancy in other ways and still deserve routine care.
Common infections during pregnancy, like colds or seasonal flu, have not been linked to Alazami syndrome. Preventing infections remains important for general fetal development.
No specific prescription or over-the-counter medicines have been shown to cause this syndrome. Medication safety in pregnancy should still be reviewed for other reasons.
Genetic risk factors
Alazami syndrome is caused by changes in a single gene that are inherited from both parents. When a child receives two nonworking copies of the LARP7 gene, the condition typically develops; carriers with one changed copy usually have no symptoms. People with the same risk factor can have very different experiences, and genetic results can help families understand recurrence risk and recognize early symptoms of Alazami syndrome.
LARP7 gene changes: Changes (mutations) in the LARP7 gene cause Alazami syndrome. Most are loss-of-function changes that prevent the gene from working as it should. Both copies of the gene need to be affected.
Autosomal recessive pattern: Alazami syndrome follows an autosomal recessive pattern. When both parents carry one nonworking copy, each pregnancy has a 25% (1 in 4) chance of an affected child. There is also a 50% (1 in 2) chance the child will be an unaffected carrier.
Two-carrier parents: Parents who both carry a LARP7 change have a higher chance of having a child with the condition. Carriers typically have no health effects. Carrier frequency can differ by ancestry and community.
Related parents: Parents who are related by blood are more likely to carry the same rare LARP7 change. This increases the chance their child inherits two copies. This pattern has been noted in families from various regions.
Family history: Having a sibling or close relative with Alazami syndrome raises the chance for future children in that family. The exact risk depends on whether parents are confirmed carriers. Genetic counseling can clarify individual family risks.
Founder variants: In some populations, a shared ancestor introduced a specific LARP7 change that appears more often. These founder variants can cluster in certain regions or communities. Knowing local patterns can refine testing in those settings.
New variant possibility: Occasionally, one LARP7 change can arise new (de novo) in a child and pair with an inherited change. This is uncommon but can explain cases without a known family history. Parental testing helps determine whether a variant is new or inherited.
Variable expressivity: Even with the same LARP7 changes, features of Alazami syndrome can vary between individuals. Differences in other genes can act like a dimmer switch and influence severity. Age can also affect when features become noticeable.
Gene copy changes: Larger deletions or duplications involving LARP7 can also cause the condition. These copy-number changes may not be detected by standard sequencing. Identifying the exact change helps estimate recurrence risk for relatives.
Lifestyle risk factors
Alazami syndrome is a genetic condition present from birth; lifestyle habits do not cause it but can influence symptom control, functional skills, and complications over time. Thoughtful daily routines can support growth, mobility, behavior, and learning. Below are practical ways how lifestyle affects Alazami syndrome. These points focus on modifiable habits and “lifestyle risk factors for Alazami syndrome,” not on genes or environment.
Consistent, nutrient-dense meals support growth and energy in children with short stature and high developmental demands. Managing textures and pacing can reduce choking or aspiration risk and make feeding more efficient.
Daily movement and prescribed home exercises help maintain joint range, balance, and bone strength. Prolonged inactivity can worsen stiffness and delay motor milestones in Alazami syndrome.
Regular, adequate sleep supports attention, mood, and learning capacity in neurodevelopmental disorders. Poor sleep can amplify daytime irritability and make therapies and school harder.
Practicing speech, occupational, and physical therapy strategies at home reinforces skills between clinic visits. Skipping home practice can slow gains in communication, fine motor ability, and mobility.
Risk prevention
There’s no way to prevent Alazami syndrome itself, since it’s a genetic condition present from birth. Prevention is about lowering risk, not eliminating it completely. The focus is on early diagnosis, steady monitoring, and steps that reduce complications over time. Knowing early symptoms of Alazami syndrome can prompt timely evaluation and support.
If Alazami syndrome runs in your family, speak with a genetics professional about carrier testing. They can discuss chances in future pregnancies and options that may fit your values.
For some families, prenatal testing or IVF with embryo testing may be options. These steps can help plan for a pregnancy and newborn care ahead of time.
If growth is far below peers or development is delayed, ask for a genetics and developmental evaluation. Earlier diagnosis of Alazami syndrome can open doors to therapies and school supports sooner.
Physical, occupational, and speech therapies can build motor, feeding, and communication skills. Starting early may lessen complications that build up over time.
Transmission
Alazami syndrome is not contagious; you can’t catch it through coughing, touch, or everyday contact. It is a genetic condition that follows an autosomal recessive pattern: most children with Alazami syndrome inherit one nonworking copy of the gene from each parent, who are typically healthy carriers.
When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of Alazami syndrome, a 50% (1 in 2) chance the child will be a carrier, and a 25% chance of inheriting no change; this risk is the same for boys and girls. Rarely, a new genetic change can occur so a child may be affected even if only one parent is known to be a carrier, and the chance is higher when parents are related by blood; a genetics professional can explain the genetic transmission of Alazami syndrome and how Alazami syndrome is inherited in your family.
When to test your genes
Test your genes if a child shows early global developmental delay, growth restriction, or distinctive facial features, especially with a family history of similar findings or consanguinity. Genetic testing confirms Alazami syndrome, guides personalized care, and clarifies recurrence risk. Consider testing before pregnancy for carrier screening when there’s known NRXN1-related history in the family.
Diagnosis
Alazami syndrome is usually identified through a mix of noticeable patterns—proportionate short stature, small head size, developmental delays, and characteristic facial features—then confirmed with specific tests. Doctors look at growth and development over time and compare findings with known features of the condition. Many people feel relief just knowing what’s really going on. When a genetic diagnosis of Alazami syndrome is confirmed, it helps guide care, supports planning, and informs family testing options.
A pediatric exam looks closely at growth (height/length, weight, and head size), facial traits, and overall development. These clinical features can raise concern for Alazami syndrome and help distinguish it from other causes of proportionate short stature.
Standardized checks of speech, learning, and motor skills document the pattern and degree of delay. Results support the clinical picture and guide referrals for therapies while evaluation continues.
A detailed family history looks for relatives with similar features, early growth concerns, or known genetic conditions. Family history is often a key part of the diagnostic conversation.
Sequencing of the LARP7 gene can confirm Alazami syndrome when a disease-causing change is found on both copies. This result provides a clear, lab-based diagnosis and clarifies recurrence risk for future pregnancies.
Stages of Alazami syndrome
Alazami syndrome does not have defined progression stages. Features usually start in early life and can vary widely, and while development changes over time, it doesn’t follow a predictable, step-by-step decline. Different tests may be suggested to help confirm the diagnosis, including a genetics test, after a doctor notices early symptoms of Alazami syndrome such as slow growth, delayed milestones, or distinctive physical features. Ongoing care typically includes regular checks of growth and development, hearing and vision tests, and targeted assessments (for example, hormone or learning evaluations) to guide supportive therapies as needs change.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with Alazami syndrome, health needs are lifelong but can be managed with a steady care plan. Growth is typically slow, intellectual disability ranges from moderate to severe, and speech is often limited, so supports for communication and learning make a big difference in day-to-day life. Some children develop seizures; these are usually treatable with standard medicines. Heart or kidney differences are less common but should be checked early, since finding and treating them promptly improves long-term health.
The outlook is not the same for everyone, but most people with Alazami syndrome live into adulthood when medical issues are identified and managed. Mortality risk is highest in early childhood if there are serious complications such as uncontrolled seizures, severe infections, or major heart defects; with proactive care and vaccinations, that risk generally decreases. Mobility can vary—from independent walking with a short stature and clumsiness, to needing assistive devices—and physical therapy helps preserve strength and balance. People living with Alazami syndrome often need help with daily routines, and consistent support for feeding and sleep can reduce stress for the whole family.
Prognosis refers to how a condition tends to change or stabilize over time. Alazami syndrome is caused by changes in the LARP7 gene, and current evidence suggests the condition is stable rather than degenerative: skills may progress slowly but typically do not fade without another medical reason. Early symptoms of Alazami syndrome—such as delayed speech and growth—can guide timely therapies that improve function and quality of life. Talk with your doctor about what your personal outlook might look like, including seizure monitoring, heart and kidney screening, vision and hearing checks, and the right mix of therapies as needs evolve.
Long-term effects
Alazami syndrome is a rare genetic condition that mainly affects growth, head size, and development as children move into adulthood. Long-term effects vary widely, so abilities and health needs can look quite different from one person to another. Families often recall early symptoms of Alazami syndrome such as slow weight gain and a smaller head in infancy, with ongoing differences in height and learning over time. These traits are typically lifelong, with changes that tend to be gradual rather than rapidly progressive.
Many have marked short height that continues from childhood into adulthood. Body proportions are usually balanced. Adult height typically remains well below average.
Head size remains smaller than peers, known medically as microcephaly. This size difference is usually present from birth and continues. Brain imaging may be otherwise unremarkable.
Developmental delay appears in early childhood and often leads to ongoing learning differences. Daily living skills can improve but typically remain below age expectations. Independence levels in adulthood vary.
Speech often develops later and remains limited compared with peers. Understanding language may be stronger than speaking. Some continue to use short phrases or simplified speech.
How is it to live with Alazami syndrome?
Living with Alazami syndrome often means navigating global developmental delays, short stature, and distinctive facial features, with many needing extra support for learning, speech, and daily skills. Medical care can involve regular visits for growth, vision, hearing, dental, and endocrine evaluations, and some families coordinate therapies like physical, occupational, and speech therapy to build independence over time. Daily life may move at a different pace, but routines, early interventions, and assistive tools can make school, play, and communication more accessible. For those around the person—parents, siblings, classmates, caregivers—it can be a team effort that blends patience with celebration of small milestones, strengthening relationships and advocacy skills along the way.
Treatment and drugs
Treatment for Alazami syndrome focuses on supportive care and addressing each person’s specific needs, since there’s no single cure for the condition. Care often includes early developmental therapies (speech, occupational, and physical therapy), educational support, vision and hearing evaluations, and nutrition guidance to support growth and feeding. Depending on features a doctor finds, specialists may manage seizures, sleep problems, scoliosis, or heart and endocrine concerns, and medicines that ease symptoms are called symptomatic treatments. Genetic counseling can help families understand inheritance and plan future care, and regular follow-up allows the team to adjust therapies as needs change. Supportive care can make a real difference in how you feel day to day.
Non-drug treatment
Daily life with Alazami syndrome often revolves around supporting growth, movement, feeding, and communication at home and school. Even if early symptoms of Alazami syndrome are subtle, starting therapies early can build important skills over time. Non-drug treatments often lay the foundation for daily function and quality of life. Care is usually team-based and tailored to each child’s strengths and needs.
Coordinated services in infancy and toddler years help build motor, language, and social skills. Therapists also coach families on simple ways to practice skills during routines.
Exercises and play-based activities improve strength, balance, and coordination. Regular PT can support sitting, standing, and walking and help prevent tight muscles and joint stiffness.
OT focuses on hand skills, dressing, feeding, and other daily activities. Therapists suggest adaptive tools and home strategies so tasks are easier and safer.
Sessions target understanding and using words, speech clarity, and social communication. Therapists also assess swallowing and can introduce communication devices if speech is limited.
Your genes may have an impact on how drugs work for you
Medicines for people with Alazami syndrome can act differently depending on inherited differences in drug-processing genes, which affect how fast a body absorbs, breaks down, or clears a dose. Clinicians may adjust medication choices or dosing and monitor closely to balance benefits and side effects.
Pharmacological treatments
For Alazami syndrome, there’s no medicine that changes the underlying genetics. Care focuses on easing symptoms that affect daily life. Drugs that target symptoms directly are called symptomatic treatments. Plans are individualized and may shift over time as early symptoms of Alazami syndrome give way to later needs.
Levetiracetam or valproate are often used if seizures occur. Not everyone responds to the same medication in the same way. Your clinician will tailor the choice and adjust the dose based on benefit and side effects.
Omeprazole or lansoprazole (proton pump inhibitors) can lessen acid reflux and protect the esophagus. Famotidine (an H2 blocker) is another option for milder symptoms. Doses and duration depend on symptom pattern and feeding needs.
Polyethylene glycol or lactulose can soften stools and ease bowel movements. Senna or bisacodyl may be added if stool remains hard or infrequent. Adequate fluids and fiber work alongside these medicines.
Melatonin at bedtime may help regulate sleep timing and quality. If sleep remains disrupted, clinicians may consider clonidine or trazodone with careful monitoring. Good sleep routines enhance the effect of any sleep aid.
Genetic influences
Alazami syndrome results from harmful changes in both copies of a gene called LARP7 that are passed down in families in a recessive pattern. When both parents carry the same gene change but feel healthy themselves, each pregnancy has a 25% (1 in 4) chance of a child with Alazami syndrome. A “carrier” means you hold the gene change but may not show symptoms. Carriers are typically healthy, while children who inherit two copies develop the condition; however, the specific features and their severity can vary, even among siblings. Testing that looks at the LARP7 gene can confirm the diagnosis and identify carriers, which helps with family planning and understanding recurrence risk. Learning about the genetic causes of Alazami syndrome can guide decisions about testing, counseling, and support for relatives.
Is Alazami syndrome genetic?
Genetics are central in Alazami syndrome. It results from inherited changes in the LARP7 gene, usually in an autosomal recessive pattern. Genetic testing confirms the diagnosis, guides family planning, and supports carrier testing for relatives.
Pharmacogenetics—how genetics influence drug effects
Genetic findings shape care for Alazami syndrome, but they rarely change the choice of a specific drug today. Changes in a gene called LARP7 confirm the diagnosis and help families understand inheritance, yet there’s currently no medicine that directly targets this pathway or reverses the condition. When medications are used to manage Alazami syndrome—such as treatments for seizures or behavior and sleep concerns, if present—dosing is adjusted to the person’s age, weight, liver and kidney function, and any other health issues. Genetic testing can sometimes identify how your body processes certain medicines, which may guide dose choices for common drugs used in supportive care, but this testing is not specific to Alazami syndrome. LARP7 changes are not known to alter the liver enzymes that break down drugs, so any helpful pharmacogenetic results usually involve other drug-metabolism genes rather than the LARP7 gene itself. Research into gene-directed therapies is ongoing, but for now treatment remains supportive and individualized, with close monitoring for benefit and side effects.
Interactions with other conditions
In day-to-day care, the short stature, small head size, and developmental delay seen in Alazami syndrome can overlap with features of other neurodevelopmental and growth disorders. Early symptoms of Alazami syndrome, such as slow growth and delayed milestones, may look similar to those of other conditions, which can make it hard to tell where one issue ends and another begins. Doctors call it a “comorbidity” when two conditions occur together. When hearing or vision problems, learning differences, or seizures are also present, they can influence therapy choices, school supports, and the way medicines are dosed. Short body size and low body weight may affect dosing for antibiotics, seizure medicines, or anesthesia if an unrelated illness or surgery is being treated. Because findings can overlap, coordinated care across genetics, pediatrics, neurology, rehabilitation, and nutrition helps align treatments and spot when another condition is driving a change in symptoms.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children who grew more slowly than their peers, spoke later, and had a mix of subtle facial features that relatives recognized but couldn’t name. Families sometimes recalled an older cousin or grandparent with similar traits. Looking back helps explain why Alazami syndrome was long missed or folded into broader developmental diagnoses.
First described in the medical literature as a cluster of developmental delays with distinctive facial features in families from the Middle East, Alazami syndrome was initially understood only through symptoms, later tied to a single gene. Early case reports focused on day-to-day signs—shorter height, slower weight gain, and learning differences—because genetic tools were limited. Doctors noted that brothers and sisters in the same family could be affected, hinting at an inherited pattern, but the exact cause remained unclear.
As medical science evolved, researchers used newer genetic testing to connect the condition to changes in a gene now known to be important for growth and development. This turned a once vague label into a defined diagnosis. In recent decades, knowledge has built on a long tradition of observation. With wider access to DNA testing across regions and healthcare systems, more families around the world were identified, showing that Alazami syndrome is not limited to a single country or ancestry.
Over time, descriptions became more complete. Clinicians recognized that features can vary: some children have more noticeable differences in facial shape, while others have milder traits; some need significant learning support, while others develop skills more gradually but steadily. These historical steps narrowed the definition, clarified how Alazami syndrome presents in early childhood, and highlighted that parents who are both carriers—often without any symptoms themselves—can have more than one child with the condition.
Today’s understanding blends these careful family histories with modern genetics. Early symptoms of Alazami syndrome—such as slower growth, speech delay, and feeding challenges in infancy—are better recognized, which helps guide timely referrals and supportive therapies. Awareness of past misunderstandings can also reassure families: what once seemed like an unexplained mix of concerns now has a name, a known cause, and a growing body of practical care advice.